MWNA
TRIL

Marshall Wace North America’s Trillium Therapeutics Inc. TRIL Stock Holding History

Marshall Wace North America’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$550K Sell
31,361
-438,898
-93% -$5.13M ﹤0.01% 1095
2021
Q2 		$4.56M Sell
470,259
-399,282
-46% -$3.76M 0.02% 574
2021
Q1 		$9.34M Sell
869,541
-794,630
-48% -$9.83M 0.04% 410
2020
Q4 		$24.5M Sell
1,664,171
-545,172
-25% -$7.86M 0.11% 211
2020
Q3 		$31.4M Sell
2,209,343
-324,446
-13% -$3.23M 0.2% 130
2020
Q2 		$20.5M Sell
2,533,789
-54,172
-2% -$335K 0.14% 171
2020
Q1 		$10.5M Buy
+2,587,961
New +$9.78M 0.08% 217

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Marshall Wace North America's TRIL Position: Q3 2021 in Review

Marshall Wace North America reduced its Trillium Therapeutics Inc. (TRIL) stake by 93% in Q3 2021, selling an estimated $5.13M and leaving 31,361 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

Marshall Wace North America first reported a position in TRIL in Q1 2020 and has held it in 7 quarters since. The position peaked at $31.4M in Q3 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Marshall Wace North America held 31,361 shares of Trillium Therapeutics Inc. worth $550K as of Q3 2021.
  • Marshall Wace North America sold 438,898 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $5.13M.
  • Trillium Therapeutics Inc. made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1095 holding.
  • Marshall Wace North America first reported a position in Trillium Therapeutics Inc. in Q1 2020 and has held it in 7 quarters since.
  • Marshall Wace North America's Trillium Therapeutics Inc. position peaked at $31.4M in Q3 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.